Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Aricept Losses Looming, Eisai Looks To Emerging Markets, Flexibility For New Growth

This article was originally published in PharmAsia News

Executive Summary

Eisai has grappled with the looming patent expiration of its blockbuster Alzheimer's disease drug Aricept, and the company has found a combination of efficiency models and belt-tightening - along with a pretty aggressive push to establish an oncology franchise - to realize growth after 2011
Advertisement

Related Content

Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept
Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept
Eisai Seeks Global Approval For Cancer Agent Eribulin As Aricept Patent Expiration Looms
Eisai Seeks Global Approval For Cancer Agent Eribulin As Aricept Patent Expiration Looms Near
Eisai Opens Fourth Knowledge Center In India As Launch Pad For Next-generation Global Products; Focus On Affordability
Quintiles And Eisai Collaborate To Develop Cancer Compounds
Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide
Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide
Advertisement
UsernamePublicRestriction

Register

SC074479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel